

LETTER

Open Access



# Letter to the Editor: A response to Hruska's case study on molecular breast imaging and the need for true tissue quantification

Richard M. Fleming<sup>1\*</sup>, Matthew R. Fleming<sup>1</sup>, Tapan K. Chaudhuri<sup>2</sup>, William C. Dooley<sup>3</sup> and Andrew McKusick<sup>1,4</sup>

**Keywords:** FMTVDM©; B.E.S.T. Imaging©, Breast cancer, Breast inflammation, Theranostics, Quantification, AI, Nuclear camera quantitative calibration, Patent protected

We applaud the efforts by Hruska et al. [1] to quantify differences in tissue using molecular breast imaging (MBI) and background parenchymal uptake (BPU); we have discussed the use of such previously [2]. The approach while commendable did not provide diagnostically useful information to differentiate tissue types. This approach, like the utilization of standardized uptake value (SUV), compares differences in background with tissue [3]. As we have already discussed [2, 4, 5] in the literature, this approach is an incorrect model, due to (1) the critical lack of standardization and calibration of nuclear cameras including both SPECT/Planar and PET; (2) the utilization of ratios which are not absolute values and therefore cannot be used to differentiate tissue based upon those issues, issues which are critical to the understanding of tissue differences; and (3) the inability to truly “measure” transitional changes in tissue, which would allow for the determination of actual treatment response on a per patient basis, saving time, money, and lives.

#### Acknowledgements

Not applicable.

#### Funding

Not applicable.

#### Availability of data and materials

Not applicable. All patent material is proprietary and require licensure.

#### Authors' contributions

Each author contributed to the subject matter within the LTE. All authors read and approved the final manuscript.

#### Authors' information

Included on cover sheet.

#### Ethics approval and consent to participate

Not applicable.

#### Consent for publication

Consent granted by all authors.

#### Competing interests

The patent was issued to the primary author by the USPTO. The other authors declare that they have no competing interests.

#### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

#### Author details

<sup>1</sup>FHHI-Omnific Imaging-Camelot, Los Angeles, CA 90245, USA. <sup>2</sup>Eastern Virginia Medical School, Norfolk, VA, USA. <sup>3</sup>Oklahoma University Health Science Center, Oklahoma City, OK, USA. <sup>4</sup>Sebec Consulting & Media, Charlotte, NC, USA.

\* Correspondence: [rmfmd7@yahoo.com](mailto:rmfmd7@yahoo.com)

<sup>1</sup>FHHI-Omnific Imaging-Camelot, Los Angeles, CA 90245, USA

Full list of author information is available at the end of the article



Published online: 29 January 2019

#### References

1. Hruska CB, Geske JR, Swanson TN, et al. Quantitative background parenchymal uptake on molecular breast imaging and breast cancer risk: a case-control study. *Breast Cancer Res.* 2018;20:46. <https://doi.org/10.1186/s13058-018-0973-3>.
2. Fleming RM, Dooley WC. Breast enhanced scintigraphy testing (B.E.S.T.) distinguishes between normal, inflammatory breast changes and breast cancer. A prospective analysis and comparison with mammography. *Integr Cancer Ther.* 2002;1(3):238–45.
3. Keys JW Jr. SUV: standard uptake or silly useless value? *J Nucl Med.* 1995;36:1836–9.
4. Fleming RM, Fleming MR, McKusick A, Chaudhuri TK. Semiquantification limitations: FMTVDM<sup>®</sup> demonstrates quantified tumor response to treatment with both regional blood flow and metabolic changes. *J Nucl Med.* 2018;59(10):1643–4. <https://doi.org/10.2967/jnumed.118.217018> published ahead of print. PMID: 30030345.
5. Fleming RM, Fleming MR, Chaudhuri TK, Dooley WC, McKusick A. FMTVDM; B.E.S.T.<sup>®</sup> imaging theranostically used to guide treatment response in a woman with recalcitrant breast cancer. *Biomed J Sci Tech Res.* 2018 ISSN: 2574-1241. DOI: <https://doi.org/10.26717/BJSTR.2018.11.002111>.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

